ReviewMolecular neurobiology2019
Procyanidins and Alzheimer's Disease.
Review in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Therapeutic benefits of flavonoids against neuroinflammation: a systematic review.Inflammopharmacology · 2022Pooled it
- Grape Seed Extract as an Adjuvant Therapy for Huntington Disease; A Narrative Review of Biological Plausibility and Potential Clinical Outcomes.Molecules (Basel, Switzerland) · 2026Review
- Chaetoglobosin F Attenuates Amyloid-β-Induced Neurotoxicity in Caenorhabditis elegans by Regulating Autophagy and Oxidative Stress Via the Insulin/IGF-1 and p38 MAPK Pathways.Neurochemical research · 2026Article
- Precise Aβ clearance and antioxidant therapy in Alzheimer's disease via photoacoustic imaging-guided palladium hydride nanosheet-mediated photothermal treatment.BMC neuroscience · 2026Article
- Procyanidins as potential anticancer agents: mechanisms of action, bioavailability challenges and therapeutic opportunities.Medical oncology (Northwood, London, England) · 2025Review
- Histone Deacetylation in Alzheimer's Diseases (AD); Hope or Hype.Cell biochemistry and biophysics · 2025Review
- Cranberry Extract Ameliorates Diabetic Cognitive Impairment in Rats Via LncRNA GAS-5 Downregulation and Pyroptosis Pathway Inhibition.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Insights Into the Therapeutic Potential of SIRT1-modifying Compounds for Alzheimer's Disease: A Focus on Molecular Mechanisms.Journal of molecular neuroscience : MN · 2025Review
- Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review.Combinatorial chemistry & high throughput screening · 2025Review
- Enhanced initiation of somatic embryos in suspension cultures ofFrontiers in plant science · 2025Article
- Investigation of oligomeric proanthocyanidins extracted from Rhodiolae Crenulatae Radix et Rhizomes using deep eutectic solvents and identified via data-dependent acquisition mass-spectroscopy.Journal of pharmaceutical analysis · 2024Article
- Alzheimer's Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models).Brain sciences · 2024Review
- Cookies Fortified with Polyphenols Extracts: Impact on Phenolic Content, Antioxidant Activity, Inhibition of α-Amylase and α-Glucosidase Enzyme, Colour and Sensory Attractiveness.Antioxidants (Basel, Switzerland) · 2024Article
- Evaluating serum CXCL12, sCD22, Lp-PLA2 levels and ratios as biomarkers for diagnosis of Alzheimer's disease.World journal of psychiatry · 2024Article
- Harnessing the Anti-Inflammatory Properties of Polyphenols in the Treatment of Inflammatory Bowel Disease.International journal of biological sciences · 2024Review
- Inhibition of α-Amylase, α-Glucosidase, Pancreatic Lipase, 15-Lipooxygenase and Acetylcholinesterase Modulated by Polyphenolic Compounds, Organic Acids, and Carbohydrates ofAntioxidants (Basel, Switzerland) · 2023Article
- Article
- Inhibitory effects and mechanisms of proanthocyanidins against enterovirus 71 infection.Virus research · 2023Article
- Macromolecular nanoparticles to attenuate both reactive oxygen species and inflammatory damage for treating Alzheimer's disease.Bioengineering & translational medicine · 2023Article
- Procyanidins Alleviated Cerebral Ischemia/Reperfusion Injury by Inhibiting Ferroptosis via the Nrf2/HO-1 Signaling Pathway.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Procyanidins, the oligomeric compounds formed from catechin and epicatechin molecules, are potentially effective targets as nutraceuticals or pharmaceuticals in the prevention and treatment of Alzheimer's disease (AD). Natural procyanidins can attenuate AD pathological features, extracellular amyloid deposits, and neurofibrillary tangles via reducing Aβ accumulation and tau pathology. The enhancement of cognition as well as modulation of synaptic plasticity by these compounds also participated in the alleviation of AD. Notably, procyanidins and some of their metabolites have been observed to upregulate SIRT1 (silent information regulator 1) which is essential for normal cognitive and synaptic plasticity, and stimulate CREB (cAMP response element binding) which acts as a molecular switch from short- to long-term memory. Based on the interplay of CREB-SIRT1 axis, it is therefore conceivable that the regulation of procyanidins by the means of CREB-SIRT1 could promote the cognitive function and is thus conducive for AD pathogenesis. This review focuses on the role of procyanidins, the main group of flavonoids, on AD and the potential mechanism involved CREB-SIRT1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.